Get ready to energize your life?
Top Offers Only Today
Support your health and step-up your mental focus
post in: Beauty, News Date:17 Oct 2017, 10:19 views:3845
1-Minute Consult, yes, if they really need one.
We would choose a cardioselective agent. Cleveland Clinic Journal of Medicine. 2010 August;77(8 498-499, eLSY viviana navas, MD, asthma department of Cardiovascular Medicine, Cleveland Clinic.
Taylor, MD, department of Cardiovascular Medicine, Critical Care Center, and Transplantation Center, Cleveland Clinic. Taylor, MD, Department of Cardiovascular Medicine, J3, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail.
Treatment with beta-adrenergic receptor blockers decreases the mortality rate in patients with coronary artery disease or heart failure, as well as during the perioperative period in selected patients (eg, those with a history of myocardial infarction, a positive stress test, or current chest pain due. The current evidence supports giving beta-blockers to patients with coronary artery disease and chronic obstructive pulmonary disease (copd) or asthma, which lowers the 1-year mortality rate to a degree similar to that in patients without copd or asthma, and without worsening respiratory function.1 However, many. THE risks, in patients with reversible airway disease, beta-blockers may increase airway reactivity and bronchospasm, as well as decrease the response to inhaled or oral beta-receptor agonists.3 Even topical ophthalmic nonselective beta-blockers for glaucoma can cause a worsening of pulmonary function.4 However, these data are.
On the other hand, not giving beta-blockers can pose a risk of death.
In a retrospective study of more than 200,000 patients with myocardial infarction, Gottlieb et al5 found that beta-blockers were associated with a 40 reduction in mortality rates in patients with conditions often considered a contraindication to beta-blocker therapy, such as congestive heart failure, pulmonary disease. Cardioselective beta-blockers, cardioselective beta-blockers with an affinity for the beta-1 receptor theoretically result in fewer adverse effects on the lungs.
They competitively block the response to beta-adrenergic stimulation and selectively block beta-1 receptors with little or no effect on beta-2 receptors, except perhaps at high doses. However, this possible high-dose effect requires further study. The effect of cardioselective beta-blockers on respiratory function was evaluated in two meta-yses,6,7 one in patients with mild to moderate reactive airway disease, the other in patients with mild to severe copd.